Top Page
RemeGen Co. Ltd. Class H
(9995)
RemeGen Co. Ltd. Class H (9995) vs. iShares MSCI Hong Kong ETF (EWH)
RemeGen Co. Ltd. Class H Business Overview & Revenue Model
RemeGen Co. Ltd. Class H Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.72B | 1.08B | 767.77M | 1.42B | 0.00 | Gross Profit |
| 1.37B | 822.99M | 497.84M | 1.36B | 0.00 | EBIT |
| -1.46B | -1.50B | -993.07M | 281.92M | -668.55M | EBITDA |
| -1.19B | -1.25B | -805.70M | 402.05M | -661.56M | Net Income Common Stockholders |
| -1.47B | -1.51B | -997.84M | 276.26M | -727.09M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 759.53M | 743.39M | 2.07B | 1.76B | 2.77B | Total Assets |
| 5.50B | 5.53B | 6.02B | 4.16B | 4.12B | Total Debt |
| 2.67B | 1.26B | 165.03M | 102.78M | 197.69M | Net Debt |
| 1.91B | 550.91M | -1.90B | -1.65B | -2.57B | Total Liabilities |
| 3.51B | 2.09B | 1.04B | 712.79M | 523.07M | Stockholders Equity |
| 1.99B | 3.44B | 4.98B | 3.45B | 3.59B |
| Cash Flow | Free Cash Flow | |||
| -1.38B | -2.35B | -2.02B | -353.71M | -1.14B | Operating Cash Flow |
| -1.11B | -1.50B | -1.26B | 263.63M | -660.08M | Investing Cash Flow |
| -248.24M | -817.65M | -841.56M | -637.95M | -479.06M | Financing Cash Flow |
| 1.39B | 978.31M | 2.43B | -626.90M | 3.90B |
RemeGen Co. Ltd. Class H Technical Analysis
RemeGen Co. Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$33.71B | ― | -56.68% | ― | 52.25% | 11.46% | |
53 Neutral | $5.24B | 3.32 | -44.36% | 6.63% | 16.78% | -0.12% | |
| $4.14B | 0.93 | -6.09% | ― | ― | ― | ||
| €3.36B | ― | -32.29% | ― | ― | ― | ||
52 Neutral | HK$33.70B | ― | -19.78% | ― | 25.96% | 39.58% | |
| HK$26.88B | 34.33 | 10.27% | 1.73% | ― | ― | ||
72 Outperform | HK$26.90B | 29.29 | 31.65% | ― | 4.23% | 47.71% |
RemeGen Co. Ltd. Class H Corporate Events
RemeGen Co., Ltd. has successfully completed the placement of 19,000,000 new H Shares, which represents approximately 9.11% of the total issued H Shares and 3.37% of the total issued Shares. This completion, which took place on May 29, 2025, resulted in an increase of the total issued Shares from 544,608,243 to 563,608,243, and the total issued H Shares from 189,581,239 to 208,581,239. The placement was conducted at a price of HK$42.44 per share to at least six independent placees, marking a significant step in the company’s capital expansion efforts.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. announced that its drug Telitacicept has received marketing approval from the National Medical Products Administration in China for treating generalized myasthenia gravis. The approval follows successful phase III clinical trials demonstrating significant efficacy and safety, with Telitacicept outperforming placebo in improving patient symptoms. This approval is expected to address the unmet medical needs of myasthenia gravis patients in China and supports RemeGen’s ongoing efforts to validate the drug’s effectiveness globally.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. has announced its 2024 Annual General Meeting (AGM) scheduled for June 26, 2025, where shareholders will consider and approve various resolutions. The agenda includes approving the 2024 financial accounts, profit distribution plan, and re-appointment of accounting firms, as well as special resolutions like issuing additional shares and amending company regulations. These decisions are pivotal for the company’s strategic direction and governance structure, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. has announced the convening of its 2025 first class meeting of H shareholders to consider significant resolutions, including the change of registered capital, the cancellation of the supervisory committee, and amendments to the company’s Articles of Association and Rules of Procedures. These proposed changes are expected to streamline the company’s governance structure and potentially enhance operational efficiency, reflecting a strategic move to strengthen its market position and stakeholder engagement.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. has established a Remuneration and Appraisal Committee to enhance its corporate governance and remuneration management system. This committee is responsible for evaluating and recommending remuneration strategies and policies for directors and senior management, as well as overseeing performance appraisals and incentive schemes. The committee’s recommendations, once approved by the Board, will be presented for consideration at the shareholders’ meeting. This move is expected to strengthen the company’s governance and align its management’s incentives with corporate goals, potentially impacting its market positioning positively.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. has announced proposed amendments to its Articles of Association to enhance corporate governance and compliance. Key changes include the cancellation of the Supervisory Committee, with its functions being transferred to the Audit Committee, and adjustments to shareholder rights and meeting procedures. These amendments aim to align with regulatory standards and are subject to shareholder approval, reflecting the company’s commitment to maintaining robust governance structures.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. announced changes to its Nomination Committee, effective May 26, 2025, with Mr. Wang Weidong stepping down and Dr. Su Xiaodi joining as a member. These changes align with the amended Corporate Governance Code and aim to enhance the company’s governance practices, improving board effectiveness and diversity.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. has announced the composition of its board of directors and their roles within the company. The board includes executive, non-executive, and independent non-executive directors, with specific members assigned to various committees such as audit, remuneration and appraisal, nomination, and strategy. This announcement provides clarity on the governance structure of the company, which could impact its strategic direction and decision-making processes.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. has established an Audit Committee under its Board to enhance internal control, audit, and related transaction systems, ensuring effective management in financial reporting, risk management, and corporate governance. This committee is responsible for reviewing the company’s financial information, supervising internal and external audits, and monitoring compliance with relevant laws and regulations, thereby strengthening the company’s governance structure.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. has established a Nomination Committee under its Board to enhance corporate governance by regulating the selection and appointment of directors. The committee is tasked with ensuring that board members possess the necessary skills, experience, and diversity to align with the company’s strategic objectives and values, while also making recommendations on appointments and succession planning for senior management.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. announced the placement of new H shares under a general mandate, with the aim of raising approximately HK$806.36 million in gross proceeds. The net proceeds, estimated at HK$796 million, will be used to further invest in the research and development of Telitacicept and for general corporate purposes. This strategic move represents around 10.02% of the existing H shares and 3.49% of the total issued shares, potentially enhancing the company’s market position and supporting its growth initiatives. The placement will be conducted by placing agents to a minimum of six independent investors, subject to certain conditions and termination rights.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
RemeGen Co., Ltd. announced that its drug, disitamab vedotin, has received marketing approval in China for treating HER2-positive advanced breast cancer with liver metastasis. This approval, based on a Phase III clinical study, marks a significant advancement in treatment options for this aggressive cancer type, potentially impacting the company’s market position and offering new hope for patients with limited treatment options.
RemeGen Co., Ltd. has released its unaudited financial data for the first quarter of 2025, prepared according to Chinese accounting principles. The report has been reviewed by the company’s audit committee but not by independent auditors, and stakeholders are advised to exercise caution when dealing with the company’s securities.
RemeGen Co., Ltd. has announced a board meeting scheduled for April 28, 2025, to consider and approve the unaudited first quarterly results for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance and could impact its market positioning and stakeholder confidence.
RemeGen Co., Ltd. held its 2025 second extraordinary general meeting (EGM) on April 2, 2025, where shareholders approved the appointment of Mr. Wen Qingkai as an executive director and member of the Strategy Committee. This appointment is expected to enhance the company’s strategic direction and governance, potentially impacting its operational effectiveness and stakeholder confidence.
RemeGen Co., Ltd. announced the composition of its board of directors and their respective roles within the company. This announcement is significant as it outlines the leadership structure, which plays a crucial role in guiding the company’s strategic direction and governance. The board includes executive, non-executive, and independent non-executive directors, with various members chairing or participating in key committees such as the Audit, Remuneration and Appraisal, Nomination, and Strategy Committees. This structured leadership is expected to enhance the company’s operational efficiency and strategic decision-making, potentially impacting its market positioning and stakeholder confidence.
RemeGen Co., Ltd. reported a significant increase in revenue for 2024, driven by strong sales of its key products, telitacicept and disitamab vedotin. The company has made notable advancements in its product pipeline, including FDA fast track designation for telitacicept for primary Sjögren’s Syndrome and achieving primary endpoints in clinical trials for generalized myasthenia gravis. Disitamab vedotin also showed promising results in various cancer treatments, enhancing RemeGen’s position in the biopharmaceutical industry.